The FDA's Latest Response to Opioid Abuse and OverdoseAschenbrenner,, Diane, S., MS, RNAJN, American Journal of Nursing: January 2018 - Volume 118 - Issue 1 - p 22–23 doi: 10.1097/01.NAJ.0000529709.78095.a2 Drug Watch Buy Abstract Author InformationAuthors Article MetricsMetrics In continuing to address prescription opioid abuse and overdose, the U.S. Food and Drug Administration (FDA) is focused on immediate-release opioids, which are frequently prescribed and may be a gateway to prescription and illegal opioid abuse. The FDA's current action plan includes policy changes within the agency, promoting the development of new abuse-deterrent generic opioids, and expanding provider education on opioid use and misuse. Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: email@example.com. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.